BOOK
Hematologic Issues in Critical Care, An Issue of Critical Nursing Clinics, E-Book
(2017)
Additional Information
Book Details
Abstract
Dr. O'Malley is a well-known nurse researcer in the area of Hemaotology, and she has assembled top experts to write about the most important hemtaologic issues in critical care. The issue has articles devoted to the following topics: Cord blood banking; Leukemia and Lymphomas; Sickle Cell; Anticoagulants; Aplastic anemia & MDS; Hereditary Hemochromatosis and Pernicious Anemia; Hemophilia; Blood book: cells, products, transfusion; Anemia; Multiple Myeloma; DIC; and The lived experience of anemia without a cause. Nurses will come away with the clinical information they need to improve patient outcomes in the critical care setting.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Hematologic Issues in Critical Care\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | v | ||
| Preface | v | ||
| Adverse Reactions to Transfusion of Blood Products and Best Practices for Prevention\r | v | ||
| Alternative to Blood Replacement in the Critically Ill\r | v | ||
| The Risks Associated with Red Blood Cell Transfusion: Implications for Critical Care Practice | v | ||
| Collaborative Strategies for Management of Obstetric Hemorrhage | vi | ||
| Balance Between the Proinflammatory and Anti-Inflammatory Immune Responses with Blood Transfusion in Sepsis | vi | ||
| Nursing Care of Adult Hematopoietic Stem Cell Transplant Patients and Families in the Intensive Care Unit: An Evidence-base ... | vi | ||
| Coagulopathy In and Outside the Intensive Care Unit | vi | ||
| Hidden Anemias in the Critically Ill | vi | ||
| Use of High-Fidelity Simulation to Increase Knowledge and Skills in Caring for Patients Receiving Blood Products | vii | ||
| Resources for Hematology On and Off the Web | vii | ||
| The Lived Experience of Anemia Without a Cause | vii | ||
| CRITICAL CARE NURSING\rCLINICS OF NORTH AMERICA\r | viii | ||
| FORTHCOMING ISSUES | viii | ||
| December 2017 | viii | ||
| March 2018 | viii | ||
| June 2018 | viii | ||
| RECENT ISSUES | viii | ||
| June 2017 | viii | ||
| March 2017 | viii | ||
| December 2016 | viii | ||
| Preface | ix | ||
| Adverse Reactions to Transfusion of Blood Products and Best Practices for Prevention | 271 | ||
| Key points | 271 | ||
| INTRODUCTION | 271 | ||
| HISTORICAL CONTEXT | 272 | ||
| ADVERSE REACTIONS TO TRANSFUSION OF BLOOD PRODUCTS | 272 | ||
| Acute Reactions | 272 | ||
| Acute hemolytic transfusion reaction | 274 | ||
| Febrile nonhemolytic transfusion reaction | 275 | ||
| Allergic and anaphylactic transfusion reactions | 275 | ||
| Transfusion-related acute lung injury | 275 | ||
| Transfusion-transmitted infections | 276 | ||
| Transfusion-associated circulatory overload | 276 | ||
| Delayed Reactions | 276 | ||
| Delayed hemolytic transfusion reaction | 276 | ||
| Posttransfusion purpura | 278 | ||
| Transfusion-related immunomodulation | 278 | ||
| Transfusion-associated graft versus host disease | 278 | ||
| BEST PRACTICES TO PREVENT OR MANAGE ADVERSE REACTIONS TO TRANSFUSION | 278 | ||
| Leukoreduction and Irradiation Before Transfusion | 278 | ||
| Storage Age of Blood Products Before Transfusion | 279 | ||
| Premedication Before Transfusion | 280 | ||
| Restrictive Transfusion Practices | 281 | ||
| Donor and Blood Screening Procedures | 281 | ||
| Cell Salvage or Autotransfusion | 284 | ||
| Reduction of Iatrogenic Anemia | 285 | ||
| SUMMARY | 285 | ||
| REFERENCES | 285 | ||
| Alternative to Blood Replacement in the Critically Ill | 291 | ||
| Key points | 291 | ||
| INTRODUCTION | 291 | ||
| IATROGENIC ANEMIA | 292 | ||
| FLUID MANAGEMENT | 294 | ||
| PHARMACEUTICALS | 295 | ||
| HEMOSTATIC AGENTS | 297 | ||
| MANUFACTURED BLOOD | 298 | ||
| WHEN BLOOD IS NOT AN OPTION | 299 | ||
| SUMMARY | 301 | ||
| REFERENCES | 302 | ||
| The Risks Associated with Red Blood Cell Transfusion | 305 | ||
| Key points | 305 | ||
| INTRODUCTION | 305 | ||
| METHOD | 306 | ||
| Study Design | 306 | ||
| Search Criteria | 306 | ||
| Study Selection | 307 | ||
| Data extraction and assessment of risk of bias | 308 | ||
| Presentation of Eligible Articles | 308 | ||
| QUALITATIVE ANALYSIS | 308 | ||
| RESULTS | 308 | ||
| DISCUSSION | 312 | ||
| Strengths and Limitations of the Systematic Review | 313 | ||
| REFERENCES | 314 | ||
| Collaborative Strategies for Management of Obstetric Hemorrhage | 315 | ||
| Key points | 315 | ||
| CAUSES OF OBSTETRIC HEMORRHAGE | 316 | ||
| HEMOSTATIC/HEMATOLOGIC ADAPTATIONS OF PREGNANCY | 316 | ||
| OBSTETRIC HEMORRHAGE AND HYPOVOLEMIC SHOCK | 318 | ||
| COMMON CARE ISSUES | 318 | ||
| GENERAL MANAGEMENT OF OBSTETRIC HEMORRHAGE | 318 | ||
| Physical Assessments | 319 | ||
| Critical Care | 319 | ||
| Goal | 319 | ||
| Quantitative assessment of blood loss | 321 | ||
| Manipulation and medication | 321 | ||
| Uterine balloon tamponade | 321 | ||
| Antishock garments | 322 | ||
| Interventional radiology | 322 | ||
| Surgical management | 323 | ||
| Intraoperative cell salvage | 323 | ||
| Acute normovolemic reinfusion | 323 | ||
| Goal | 324 | ||
| Oxygenation | 324 | ||
| Volume replacement | 324 | ||
| Blood component therapy | 324 | ||
| Massive transfusion protocol | 325 | ||
| Other considerations | 325 | ||
| Goal | 326 | ||
| Coagulopathies | 326 | ||
| Complications | 327 | ||
| CONSIDERATIONS FOR OPTIMIZING CARE | 327 | ||
| Preparation | 327 | ||
| Communication | 328 | ||
| A Family-Centered Approach | 328 | ||
| SUMMARY | 328 | ||
| REFERENCES | 328 | ||
| Balance Between the Proinflammatory and Anti-Inflammatory Immune Responses with Blood Transfusion in Sepsis | 331 | ||
| Key points | 331 | ||
| INTRODUCTION | 331 | ||
| Immunomodulation from Blood Transfusion | 332 | ||
| Leukocytes | 332 | ||
| Nonpolar lipids and lysophosphatidylcholines | 333 | ||
| Erythrocytes | 333 | ||
| Microparticles | 334 | ||
| Host Immune Response in Sepsis | 335 | ||
| Blood Transfusion in Sepsis | 335 | ||
| Transfusion goals | 335 | ||
| Patient mortality | 335 | ||
| Effect on immune mediators | 336 | ||
| Infection | 336 | ||
| SUMMARY | 336 | ||
| REFERENCES | 337 | ||
| Nursing Care of Adult Hematopoietic Stem Cell Transplant Patients and Families in the Intensive Care Unit | 341 | ||
| Key points | 341 | ||
| LITERATURE SEARCH | 342 | ||
| ADMISSION TO INTENSIVE CARE UNIT | 343 | ||
| Criteria for Admission | 343 | ||
| Average Stay in Intensive Care Unit | 343 | ||
| Morbidity | 343 | ||
| Mortality | 344 | ||
| INTERVENTION RECOMMENDATIONS | 344 | ||
| STAFF INTERVENTIONS | 344 | ||
| Education | 344 | ||
| Specific Care | 346 | ||
| Communication | 347 | ||
| Support | 347 | ||
| PATIENT INTERVENTIONS | 347 | ||
| Education and Specific Care | 348 | ||
| Communication | 348 | ||
| Support | 348 | ||
| FAMILY INTERVENTIONS | 348 | ||
| Specific Care | 348 | ||
| Education | 349 | ||
| Communication | 349 | ||
| Support | 349 | ||
| SUMMARY | 350 | ||
| REFERENCES | 350 | ||
| Coagulopathy In and Outside the Intensive Care Unit | 353 | ||
| Key points | 353 | ||
| INTRODUCTION | 353 | ||
| COAGULOPATHY OF CRITICAL ILLNESS | 353 | ||
| Sepsis | 353 | ||
| Trauma | 354 | ||
| Obstetric Disseminated Intravascular Coagulation | 355 | ||
| Hepatic Insufficiency | 355 | ||
| Cardiopulmonary Bypass | 355 | ||
| MEDICATION-INDUCED COAGULOPATHY | 355 | ||
| CONGENITAL COAGULOPATHY | 355 | ||
| DIAGNOSIS/TECHNIQUES | 356 | ||
| Plasma-Based Coagulation Assays | 356 | ||
| Viscoelastic Hemostatic Assays | 356 | ||
| PROGNOSIS/CLINICAL MANAGEMENT: BLOOD PRODUCTS | 356 | ||
| REVERSAL AGENTS | 357 | ||
| Antiplatelet Drugs | 357 | ||
| Heparin and Heparinoids | 357 | ||
| Warfarin | 357 | ||
| Novel Oral Anticoagulants | 357 | ||
| CONTROVERSIES | 358 | ||
| Point-of-Care Testing | 358 | ||
| Tranexamic Acid | 358 | ||
| Single-Factor Therapy | 358 | ||
| Massive Transfusion Protocols | 358 | ||
| SUMMARY | 359 | ||
| REFERENCES | 359 | ||
| Hidden Anemias in the Critically Ill | 363 | ||
| Key points | 363 | ||
| TREATMENT WITHOUT TRANSFUSION | 364 | ||
| EMERGING EVIDENCE—MIXED RESULTS | 366 | ||
| The Future | 367 | ||
| REFERENCES | 367 | ||
| Use of High-Fidelity Simulation to Increase Knowledge and Skills in Caring for Patients Receiving Blood Products | 369 | ||
| Key points | 369 | ||
| INTRODUCTION | 369 | ||
| BACKGROUND | 369 | ||
| History of Simulation | 369 | ||
| USE OF SIMULATION FOR BLOOD TRANSFUSION MANAGEMENT COMPETENCY | 371 | ||
| Simulation Standards for Best Practice: Simulation | 371 | ||
| SUMMARY | 374 | ||
| REFERENCES | 374 | ||
| Resources for Hematology On and Off the Web | 377 | ||
| Key points | 377 | ||
| INTRODUCTION | 377 | ||
| EVIDENCE-BASED PRACTICE | 378 | ||
| GRADING SCALES | 379 | ||
| PROFESSIONAL HEMATOLOGY RESOURCES | 379 | ||
| DATABASES | 379 | ||
| ORGANIZATIONS | 380 | ||
| JOURNALS | 381 | ||
| BOOKS | 383 | ||
| CONSUMER HEALTH HEMATOLOGY RESOURCES | 384 | ||
| SUMMARY | 385 | ||
| REFERENCES | 386 | ||
| The Lived Experience of Anemia Without a Cause | 389 | ||
| Key points | 389 | ||
| AUTHOR’S NOTE TO THE READER | 389 | ||
| DECEMBER | 390 |